Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Clinical trial NCT03298984 · COMPLETED
Trial details
- NCT number
- NCT03298984
- Sponsor
- Sumitomo Pharma America, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-25
- Primary completion
- 2020-03-20
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.